Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

– Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall 2025 –

Read more at globenewswire.com